VivoSeq
Other

Central Nervous System

1

Pipeline Programs↗

7

Active Trials↗

12

Companies Involved↗

Central Nervous System is an early-stage landscape with 1 program across 12 companies. The most active players are Bayer, Haisco-USA Pharmaceuticals, Inc., Bristol-Myers Squibb.

Intelligence

Pipeline Metrics

Competitive Density

25/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

77/100

Attrition Rate

19/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Bayer logo

Bayer

1 program

PreclinicalH

Haisco-USA Pharmaceuticals, Inc.

0 programs

PreclinicalBristol-Myers Squibb logo

Bristol-Myers Squibb

0 programs

PreclinicalTakeda logo

Takeda

0 programs

PreclinicalAstraZeneca logo

AstraZeneca

0 programs

PreclinicalOtsuka logo

Otsuka

0 programs

Preclinical

Pipeline

Programs by Phase

Preclinical1

Gadobutrol

Bayer

Phase 1
No programs
Phase 2
No programs
Phase 3
No programs
Approved
No programs

Analysis

Trial Status

59

clinical trials

Completed36 · 61%
Terminated7 · 12%
Unknown status5 · 8%
Withdrawn4 · 7%
Recruiting4 · 7%
Not yet recruiting2 · 3%
Other1 · 2%

Clinical Trials

Trial Activity

59 trials

Gadolinium and Ferumoxytol MRI in Diagnosing Patients With Abnormalities in the Central Nervous System
Recruiting·OOHSU Knight Cancer Institute·Phase 2·NCT03270059·150 enrolled
Palbociclib and Pembrolizumab In Central Nervous System Metastases
Recruiting·MMassachusetts General Hospital·Phase 2·NCT02896335·45 enrolled
High-dose Furmonertinib for First-line Treatment of EGFR Mutated NSCLC With Central Nervous System (CNS) Metastases
Recruiting·HHunan Province Tumor Hospital·Phase 2·NCT05379803·40 enrolled
A Prospective, Multicenter Phase 2/3 Study to Assess the Efficacy and Safety of Mangaciclanol in Adult Patients With Known or Highly Suspected Lesions Referred for Contrast-Enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) or Body (LUMINA)
Recruiting·GGE Healthcare·Preclinical·NCT07472491·640 enrolled
Investigation of Individualised Antisense Oligonucleotides (ASOs) in People With Unique Genetic Variants Causing Severely Debilitating, Life Threatening (SDLT) Central Nervous System (CNS) Conditions
Active, not recruiting·EEveryONE Medicines Inc.·Phase 1/2·NCT07410143·1 enrolled
Inflammation in Primary and Secondary Malignancies of the Central Nervous System Using [C-11]-CS1P1
Not yet recruiting·WWashington University School of Medicine·Phase 2·NCT07462507·104 enrolled
Molecular Subtype-Guided R-CHOP-MTX±Zanubrutinib Treatment in Newly Diagnosed DLBCL Patients with Central Nervous System Involvement
Not yet recruiting·TThe First Affiliated Hospital with Nanjing Medical University·Phase 2·NCT06594432·40 enrolled
Part 1: Dose-Finding of HSK3486 Injection In Nondependent, Recreational Central Nervous System Depressant Users
Completed·HHaisco-USA Pharmaceuticals, Inc.·Phase 1·NCT07404306·43 enrolled
Study to Evaluate the Abuse Potential of AZD7325 in Healthy Recreational Central Nervous System (CNS) Depressant Users
Completed·AstraZeneca logoAstraZeneca·Phase 1·NCT00902772·100 enrolled
Safety and Efficacy of Gadobutrol 1.0 Molar ( Gadavist ) in Patients for Central Nervous System (CNS) Imaging
Completed·Bayer logoBayer·Phase 3·NCT00623467·343 enrolled
Vorinostat Combined With Isotretinoin and Chemotherapy in Treating Younger Patients With Embryonal Tumors of the Central Nervous System
Completed·National Cancer Institute (NCI)·Phase 1·NCT00867178·33 enrolled
MARCH Central Nervous System Substudy
Completed·KKirby Institute·N/A·NCT01637233·28 enrolled
Effect of Probiotics on Central Nervous System Functions in Humans
Completed·UUniversity Hospital Tuebingen·Phase 2/3·NCT02793193·54 enrolled
Acyclovir for Herpes Infections Involving the Central Nervous System in Neonates
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 3·NCT00031460·46 enrolled
Beta2-mimetic and Central Nervous System
Completed·UUniversity Hospital, Grenoble·N/A·NCT02925130·15 enrolled
Page 1 of 4

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)